top of page
Browse by category
Search
FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults
Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas. "Ev
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
Apollo’s ESG and REVISE Systems approved by FDA
Apollo Endosurgery has been granted marketing authorisation for its ESG, ESG Sx, REVISE and REVISE Sx through the FDA’s De Novo...
Spatz Medical’s first adjustable gastric balloon, the Spatz3 Gastric Balloon, approved in US
The FDA has approved the Spatz Medical’s Spatz3 Gastric Balloon, the first adjustable gastric balloon system, to aid in weight loss for...
FDA approves Novo Nordisk’s Wegovy (semaglutide 2.4 mg) for weight management
The FDA has approved Novo Nordisk’s Wegovy (the brand name for once-weekly semaglutide 2.4mg injection in the US) for chronic weight...
Browse by tag
bottom of page